Chronic hepatitis B: a critical discussion

Telbivudine (LdT) is an antiviral agent currently used in the treatment of chronic hepatitis B virus, which was first approved by the US FDA in 2006. The safety of LdT is of great importance for patients that receive long-term treatment for this condition. It has been confirmed that patients treated...

Full description

Saved in:
Bibliographic Details
Published inFuture virology Vol. 12; no. 3; pp. 111 - 117
Main Authors Long, Jianfei, Wang, Min, Chen, Bicui, Zhang, Jiming, Wang, Bin
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 01.03.2017
Subjects
Adenosine
adverse reactions
Antiviral drugs
Chronic infection
Creatine
Creatine kinase
Deoxyribonucleic acid
DNA
DNA polymerase
Drug dosages
Enzymes
Genomes
HBV
Hepatitis
Hepatitis B
Hepatitis B virus
Hepatology
Kinases
LdT
Metabolism
Mitochondrial DNA
Oxidative stress
Research methodology
Side effects
telbivudine
Viruses
United States > US
Online AccessGet full text

Cover

More Information
Summary:Telbivudine (LdT) is an antiviral agent currently used in the treatment of chronic hepatitis B virus, which was first approved by the US FDA in 2006. The safety of LdT is of great importance for patients that receive long-term treatment for this condition. It has been confirmed that patients treated with LdT have significantly elevated creatine kinase levels. However, the mechanism responsible for this adverse reaction is unclear. This review summarizes the current literature of the adverse reactions of LdT and the possible mechanisms that are involved in chronic hepatitis B infection. Thus, we aim to provide guidance on best practices in using LdT and to provide evidence of the possible mechanisms of LdT-associated adverse reactions.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1746-0794
1746-0808
DOI:10.2217/fvl-2016-0094